Evidence map›Paper›PMID 31880858›Full record

ArticleJournal of diabetes investigation2020

Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.

Daisuke Yamazaki, Yoshio Konishi, Takashi Morikawa, Hideki Kobara, Tsutomu Masaki, Hirofumhi Hitomi, Kenji Osafune, Daisuke Nakano, Wararat Kittikulsuth, Akira Nishiyama

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Daisuke YamazakiDepartment of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Yoshio KonishiDivision of Nephrology and Hypertension, Osaka City General Hospital, Osaka, Japan.
Takashi MorikawaDivision of Nephrology and Hypertension, Osaka City General Hospital, Osaka, Japan.
Hideki KobaraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Tsutomu MasakiDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Hirofumhi HitomiDepartment of iPS Stem Cell Regenerative Medicine, Kansai Medical University, Osaka, Japan.
Kenji OsafuneDepartment of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0001-7238-2763
Daisuke NakanoDepartment of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Wararat KittikulsuthDepartment of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Akira NishiyamaDepartment of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.ORCID https://orcid.org/0000-0001-5971-820X
Kagawa University · JPOsaka City General Hospital · JPKansai Medical University · JPKyoto University · JP

Funding

Taisho Pharmaceuticals Co., Ltd.
6 · The paper itself

Abstract

AIMS/

introductionClinical studies have shown that treatment with inhibitors of sodium-glucose cotransporter 2 (SGLT2) significantly increases the hematocrit in patients with type 2 diabetes. To investigate whether SGLT2 inhibitors directly promote erythropoietin production independently on blood glucose reduction, the hematopoietic effect of the specific SGLT2 inhibitor, luseogliflozin, was examined in non-diabetic rats with renal anemia. MATERIALS AND

methodsRenal anemia was induced by treatment with adenine (200 or 600 mg/kg/day, orally for 10 days) in non-diabetic Wistar-Kyoto or Wistar rats, respectively. Luseogliflozin (10 mg/kg bodyweight) or vehicle (0.5% carboxymethyl cellulose) was then administered for 6 weeks. The hematocrit and the hemoglobin (Hb), blood urea nitrogen, plasma creatinine, and plasma erythropoietin levels were monitored.

resultsTreatment with adenine decreased the hematocrit and the Hb level, which were associated with increases in the blood urea nitrogen and plasma creatinine levels. In Wistar-Kyoto rats treated with 200 mg/kg/day adenine, administration of luseogliflozin induced glycosuria, but did not change the blood urea nitrogen, plasma creatinine levels, hematocrit, Hb or plasma erythropoietin levels. Similarly, luseogliflozin treatment failed to change the hematocrit or the Hb levels in Wistar rats with renal anemia induced by 600 mg/kg/day of adenine. Plasma erythropoietin concentrations were also not different between luseogliflozin- and vehicle-treated rats. Similarly, in human erythropoietin-producing cells derived from pluripotent stem cells, luseogliflozin treatment did not change the erythropoietin level in the medium.

conclusionsThese data suggest that SGLT2 inhibitor fails to exert hematopoietic effects in non-diabetic conditions.

Indexed as

AdenineAnemiaAnimalsDisease Models, AnimalErythropoietinHematocritHematopoietic Stem CellsHemoglobinsHumansKidneyMaleRatsRats, Inbred WKYRats, WistarRenal InsufficiencySodium-Glucose Transporter 2 Inhibitors1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitolAdenineErythropoietinHemoglobinsSodium-Glucose Transporter 2 InhibitorsSorbitolErythropoietinRenal anemiaSodium-glucose cotransporter 2 inhibitor

Identifiers

PMID31880858
PMCPMC7378420
OpenAlexW2998541672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.